The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid ongoing legal challenges facing major healthcare corporations, a Los Angeles judge has declared a mistrial in a lawsuit against Johnson & Johnson. The decision followed the jury's failure to reach a unanimous verdict regarding allegations that a woman's death from mesothelioma was caused by asbestos in the company's talc products. According to reports, jurors were deadlocked on whether the dose of asbestos was sufficient to cause cancer, despite agreeing on the presence of the mineral in the products.
This trial is part of thousands of lawsuits filed against JNJ, which the company is attempting to resolve through a $6.475 billion settlement offer within a subsidiary bankruptcy plan, per company financial reports. In comparison to peers, companies like Bayer face similar litigation cycles regarding their products, with markets monitoring healthcare sector volatility due to these massive legal liabilities. Mistrials due to jury deadlocks are common in talc litigation and typically represent a delay in resolution rather than a definitive legal victory or defeat, per market data.
Sign in to access this content
Sign InJNJ shares closed at $263.04 (as of July 02, 2026), having reached a session high of $263.1. Investors are now watching for progress on the company’s comprehensive settlement plan to exit the litigation cycle. On the macroeconomic front, traders are awaiting speeches from Federal Reserve officials, including Fed Barkin’s speech scheduled for June 28, 2026, for signals on monetary policy directions that could impact defensive sector valuations.